Printer Friendly

Pitfalls in diagnostic Gastrin measurements.

Gastrin was the first gastrointestinal hormone to be measured in plasma (1-4). Great expectations surrounded gastrin research around 1970, because peptic ulcer was a widespread disease in which gastrin was assumed to play a central role (5, 6). Moreover, gastrin was expected to be part of the flawed incretin mechanism in type 2 diabetes (7). The subsequent discovery of gastrin gene expression in major cancers suggested that gastrin might be a carcinogenetic growth factor (8). Finally, the Zollinger-Ellison syndrome (ZES)(4) turned out to be caused by gastrinomas (9) that required gastrin measurements for proper diagnosis.

Today, the picture is changed: Peptic ulcer is caused by Helicobacter pylori infection and does not need gastrin measurement for diagnosis. The incretins glucagon-like peptide 1 and gastric inhibitory polypeptide have nearly eliminated the diabetes-related interest in gastrin (10). In addition, gastrin has not advanced to the major league of growth factors in cancer (11). On the other hand, small gastrinomas that produce mild ZES symptoms are now found with increased frequency (12), thus requiring gastrin measurement of at least 200 plasma samples per million individuals per year (13).

Analytical Issues

Alongside the clarification of the diagnostic indication for gastrin measurement, several analytical issues exist. First, there is the basic question of the molecular nature of circulating gastrin. Originally, gastrin was identified as a single peptide, gastrin-17 (14) (Fig. 1). We now know that normal antral G cells synthesize 6 bioactive gastrins, of which 5 (gastrin-71, -52, -34, -17, and -14) circulate as pairs of O-sulfated and nonsulfated peptides (15-17). Of these peptides, gastrin-34 and gastrin-17 are the major forms in normal plasma (1517). Although each of the gastrins are equallybioactive in vitro (16, 17), their in vivo metabolic clearance from the circulation varies widely. For instance, the half-life of gastrin-34 is 40 min in humans, but that of gastrin-17 is only 4 min (18). Consequently, in states of gastrin hypersecretion, such as achlorhydria and gastrinomas, the longer gastrin peptides predominate in plasma (19, 20). Some plasmas even contain only long gastrins and no gastrin-17 (19).

[FIGURE 1 OMITTED]

The second issue is the molecular heterogeneity of gastrin, which challenges the immunochemical specificity of gastrin assays. Most diagnostic assays use antibodies that have been produced against some form of gastrin-17 (Fig. 1). Gastrin-17 and its analogs are robust peptides that are easily directionally coupled to immunogenic carrier proteins for antibody production. Generally, conventional gastrin immunization in rabbits produces high-affinity antibodies with titers so high that the antisera can be used for decades. Our laboratory still uses a >40-year-old antiserum from a single rabbit for routine diagnostic measurements (21). The decisive question, however, is to what extent antibodies raised against gastrin-17 bind the other gastrins. The reactivity varies considerably with respect to both peptide length and amino acid derivatizations (22, 23). Consequently, antibodies require careful evaluation to define both the epitope and reactivity against longer and shorter forms of gastrin, sulfated as well as nonsulfated. As an absolute minimum, the binding of sulfated and nonsulfated gastrin-17--as well as gastrin-34 and cholecystokinin-8 (CCK-8) (Fig. 1)--must be tested. Only antibodies that bind gastrin-17 and gastrin-34 equally, without the influence of O-sulfation of the tyrosyl residue, are useful in diagnostic immunoassays (24).

The third issue is the biology of gastrinomas. Gastrinomas are generally slowly growing neuroendocrine tumors. In gastrinoma cells, progastrin is processed less efficiently than in normal gastrin cells (8,25). Although gastrinoma cells generallyrelease more progastrin, processing intermediates, and long forms of gastrin (gastrin-71, -52, and -34), each gastrinoma displays a highly individual biosynthetic pattern (19, 24) with respect to both endoproteolytic cleavages and amino acid derivatizations (26-28). Taken together with the differences in clearance from the circulation, the variable efficiency of the tumors to synthesize gastrin introduces large individual variation in the gastrin concentration and molecular gastrin pattern in the plasma of gastrinoma patients (19, 24, 27).

The fourth issue is the shift from assays developed in academic research laboratories in the 1970s and early 1980s to kits produced by diagnostics companies. Thus, most diagnostic gastrin measurements carried out today in hospitals and private clinical chemistry laboratories are based on commercial assays (RIAs or ELISAs). An examination of the manufacturers' instructions indicate that the new insights into gastrin biochemistry and gastrinoma biology that have occurred in recent decades have not been followed up. Consequently, the antibodies in some kits have not been adequatelyexamined and selected for the diagnosis ofZES patients.

The Clinical Situation

In the 1960s and 1970s, most diagnosed ZES cases were clinically fulminant. Patients had massive hypersecretion of hydrochloric acid from an enlarged and folded gastric mucosa, severe and often multiple duodenal and jejunal ulcers, diarrhea, nanomolar gastrin concentrations in the plasma, frequent occurrence of metastases, and a high mortality rate (29, 30). But in synchrony with the dissemination of the first sensitive RIAs, the clinical picture changed to more frequent incidences (5 new ZES patients per year in Denmark, which has 5 million inhabitants) and patients with milder symptoms and only moderate increases in gastrin concentrations in plasma [104-1040 pg/mL (50500 pmol/L) gastrin; reference interval, <104 pg/mL (<50 pmol/L)]. The new gastrin RIAs were simply allowing ZES patients to be diagnosed at an earlier stage of the disease. Moreover, when proton pump inhibitors were introduced in the late 1980s, the symptoms of gastrinoma patients were treated efficiently (31), which allowed proper time for localization and removal of the gastrinomas and for management of the long-term complications of tumor growth. Proton pump inhibitor treatment itselfincreases the secretion ofgastrin from normal antral G cells. Therefore, there is a risk of overdiagnosing proton pump inhibitortreated patients with ZES symptoms and with moderately increased gastrin concentrations in the plasma. There are procedures, however, including the secretin provocation test, to rule out this risk (32).

The new picture, however, also included a group of patients with ZES symptoms but apparently normal gastrin concentrations in plasma. These patients have been estimated to constitute 0.3%-3% of all gastrinoma patients (33). Some of these patients developed multiple duodenal/jejunal ulcers, intestinal perforations, and/or bleeding, diarrhea, and severe acid vomiting, despite gastrin concentrations in the plasma that remained normal or near normal (24). Considering, on the one hand, the complex biosynthesis, the immunochemical specificity problems, and the gastrinoma biology, and, on the other hand, the increased use of commercial gastrin kits in the years with a growing incidence of patients with ZES symptoms but apparent normogastrinemia, an examination of the analytical specificity and diagnostic sensitivity of the kits seemed due.

Kit Evaluation

From our catalog and Internet searches, we discovered that the market offered 12 gastrin kits--7 RIAs and 5 ELISAs. We used these kits in accordance with the manufacturers' instructions (24). For reference, we used a thoroughly evaluated in-house RIA. This RIA had been shown to measure all circulating bioactive forms of gastrin with equimolar potency, irrespective of the N-terminal sequence length and the degree of tyrosyl sulfation. In addition, the reference assay did not cross-react with CCK peptides (Fig. 1) (15, 21, 24, 34). We analyzed plasma samples from 40 fasting patients with a ZES diagnosis and who either had proven gastrinomas or were strongly suspected of having gastrinomas but that had not yet been localized. The reference assay showed that the plasma concentrations varied from <208 pg/mL (<100 pmol/L) to 129 605 pg/mL (62 340 pmol/L). The kits and the reference assay were also evaluated with known concentrations of synthetic gastrin peptides (gastrin-14, -17, -34, and -52, in both O-sulfated and unsulfated forms) spiked into plasma samples from which endogenous gastrins had been removed by immunosorption. Finally, plasma samples with "false" gastrin concentrations were subjected to gel chromatography monitored with the reference assay and the gastrin kits that had produced "false" concentrations.

[FIGURE 2 OMITTED]

The results showed that 4 kits frequently produced measured concentrations that were too low; 3 other kits often measured concentrations that were too high. Thus, only 5 kits exhibited acceptable diagnostic trueness. The specificity test with synthetic peptides and the chromatographic analysis also provided an explanation: the "false" low concentrations were due to antibodies that recognized only gastrin-17 and not longer or shorter gastrins (Fig. 2). Three of the gastrin-17specific kits also overreacted with sulfated gastrin-17 to different degrees, adding to the complexity and incommensurability of the measurements. The 3 kits that produced falsely high results also overreacted with sulfated gastrins and/or were subject to nonspecific interference from plasma proteins (24).

The diagnostic sensitivities of the kits have been compared with respect to the probability of measuring truly increased gastrin concentrations that are diagnostic for ZES patients (Table 1). Note that the probabilities in the table are based on ZES samples with gastrin concentrations of only 104-1247 pg/mL (50-600 pmol/L). It is these patients with slightly to moderately increased gastrin concentrations and moderate clinical symptoms who constitute today's diagnostic challenge. The problems for patients with a delayed ZES diagnosis are that their symptoms become fulminant and that they have a high mortality rate because of disseminated, metastatic gastrinomas. The diagnosis of patients with such fulminant ZES symptoms and nanomolar gastrin concentrations in plasma is straightforward and is not missed by any gastrin kit. But then it is often too late.

Gastrin-17-Specific Antibodies

Gastrin-17 constitutes only a minor fraction of the gastrins in ZES plasma and is, as previously mentioned, even absent in some samples. Assays that use gastrin17-specific antibodies will therefore often produce concentration measurements that are too low. Why then were the antibodies used in the original gastrin RIAs (1-4, 21) all directed against the C-terminal epitope and hence measured all bioactive gastrins? The explanation may be simple. As shown in Figs. 1 and 3, the N terminus of gastrin-17 is a pyroglutaminyl residue. Consequently, the intact gastrin-17 peptide is without free N[H.sub.2] groups for carrier coupling, and gastrin-17 is without lysyl residues, with their e-NH2 group. The first useful gastrin RIA antibodies were raised by McGuigan against truncated gastrin 2-17 with a free N-terminal NH2 group (35). Subsequent attempts to raise antibodies have often used McGuigan's protocol. Therefore, the antibodies raised in this way were specific for the C-terminal epitope. If the intact gastrin 1-17 peptide is used for immunization instead, only the glutamic acid residues in the middle of the sequence are available for conventional coupling reactions (Figs. 1 and 3). The carrier-coupled gastrin 1-17 will then expose only the short N-terminal and C-terminal sequences, and, accordingly, some antibodies will require the combined N- and C-terminal epitope from gastrin-17 for binding (Fig. 3) and therefore become entirely specific for untruncated gastrin-17. Consequently, the lesson is to use either N-terminally truncated gastrin for immunization or N-terminally truncated gastrin-17 as a tracer peptide to pick up only C-terminally directed gastrin antibodies.

CCK Interference

CCK is the only naturally occurring peptide system in plasma that is closely related to gastrin. CCK and gastrin peptides have the same C-terminal sequence (Fig. 1); therefore, both are ligands for the gastrin/CCK-B receptor. Consequently, some C-terminally directed gastrin antibodies will also bind CCK, but the extent to which this occurs varies (21). Thus far, CCK interference in gastrin assays has been considered unimportant because CCK normally circulates at concentrations 10- to 20-fold lower than those of gastrin (36). A few CCK-producing tumors have been described (8, 37), but none have yet been reported in patients with enhanced plasma concentrations and hypercholecystokininemia-related symptoms. Such tumors may occur, however. The bottom line, therefore, is that the reactivity with CCK peptides in diagnostic gastrin assays should also be examined.

Second-Line Assays

When immunoassays that measure the C-terminal epitope of bioactive gastrins (first-line assays) are used, almost all patients with ZES are correctly diagnosed. A few gastrinomas, however, may process progastrin so poorly that the concentrations of bioactive amidated gastrins in plasma periodically fluctuate into the reference interval [104 pg/mL (<50 pmol/L)] while the concentrations of precursors are increased (27, 38). For these patients, we have designed a processing-independent analysis (39, 40). Processing-independent analyses use high-avidity antibodies that are monospecific for a non-processed precursor sequence. The sequence must be located immediately C-terminal to a trypsin-sensitive cleavage site. Monospecificity of the antibodies is ensured by immunization with short peptides (decapeptides to pentadecapeptides) directionally coupled at their C-terminus. A monoiodinated tracer is prepared by labeling a naturally occurring or a synthetically coupled tyrosyl residue in a position C-terminal to the antibody-bound sequence. By cleavage with trypsin (or another suitable endoprotease) before measurement, the selected epitope on the precursor is exposed for antibody binding. Moreover, the tryptic cleavage ensures that the peptide fragment to be measured always has the same size, i.e., the minimal tryptic fragment. With such a fragment used as a calibrator, the preanalytical trypsin treatment ensures optimal trueness, because the substance to be measured always corresponds to the calibrator. The described approach ensures that the translational product is quantified accurately, irrespective of the degree of posttranslational processing. In other words, 1 peptide fragment is mea sured stoichiometrically per translated propeptide molecule.

[FIGURE 3 OMITTED]

Processing-independent assays have been useful as second-line assays for a few gastrinomas with truly normal or only slightly increased plasma concentrations of amidated gastrins (27, 38). The ability to diagnose selected gastrinomas at an early stage of the disease via processing-independent analysis is therefore valuable.

Conclusion

It is challenging that peptide hormones display a biology and pathology considerably more complex than originally assumed. Gastrin illustrates the situation. Today, proper laboratory diagnosis requires assays that take the full biogenetic, immunochemical, and tumorbiological complexity into account. Gastrinomas are slowly growing neuroendocrine tumors that have to be diagnosed early, because the symptoms and the mortality rate for disseminated gastrinomas are severe. It is not acceptable that insufficient examination of assay specificity and diagnostic sensitivity may cause lifelong invalidity or early death. We hope the present review inspires a proper evaluation of immunoassays.

Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.

Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the Disclosures of Potential Conflict of Interest form. Potential conflicts of in terest:

Employment or Leadership: None declared.

Consultant or Advisory Role: None declared.

Stock Ownership: None declared.

Honoraria: None declared.

Research Funding: J.F. Rehfeld, Danish Medical Research Council, Danish Cancer Union, Lundbeck Foundation, and Novo Nordisk Foundation.

Expert Testimony: None declared.

Acknowledgments: The skillful secretarial assistance of Diana Skovgaard is gratefully acknowledged. The biochemical and clinical studies upon which this review is based were supported by grants from the Danish Medical Research Council, the Danish Cancer Union, the Lundbeck Foundation, and the Novo Nordisk Foundation.

References

(1.) McGuigan JE, Trudeau WL. Immunochemical measurement of e evated levels of gastrin in the serum of patients with pancreatic tumors of the Zollinger-Ellison variety. N Engl J Med 1968;278: 1308-13.

(2.) Hansky J, Cain MD. Radioimmunoassay of gastrin in human serum. Lancet 1969;2:1388-90.

(3.) Yalow RS, Berson SA. Radioimmunoassay of gastrin. Gastroenterology 1970;58:1-14.

(4.) Stadil F, Rehfeld JF. Radioimmunoassay of gastrin in human serum. Scand J Gastroenterol Suppl 1971;6:61-5.

(5.) Kirsner JB. Peptic ulcer; review of the literature for 1964. Gastroenterology 1965;49:79-106.

(6.) Walsh JH, Grossman MI. Gastrin (first of two parts). N Engl J Med 1975;292:1324-34.

(7.) Dupre J, Curtis JD, Unger RH, Waddell RW, Beck JC. Effects of secretin, pancreozymin, or gastrin on the response of the endocrine pancreas to administration of glucose or arginine in man. J Clin Invest 1969;48:745-57.

(8.) Rehfeld JF, van Solinge WW. The tumor biology of gastrin and cholecystokinin. Adv Cancer Res 1994;63:295-347.

(9.) Gregory RA, Grossman MI, Tracy HJ, Bentley PH. Nature of the gastric secretagogue in Zollinger-Ellison tumours. Lancet 1967;2:543-4.

(10.) Rehfeld JF. Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides. Acta Physiol 2011;201:405-11.

(11.) Aaronson SA. Growth factors and cancer. Science 1991;254:1146-53.

(12.) Wolfe MM, Jensen RT Zollinger-Ellison syndrome. Current concepts in diagnosis and management. N Engl J Med 1987;317:1200-9.

(13.) Jacobsen O, Bardram L, Rehfeld JF. The requirement for gastrin measurements. Scand J Clin Lab Invest 1986;46:423-6.

(14.) Gregory H, Hardy PM, Jones DS, Kenner GW, Sheppard RC. The antral hormone gastrin. Structure of gastrin. Nature 1964;204:931-3.

(15.) Rehfeld JF. Gastrins in serum. A review of gastrin radioimmunoanalysis and the discovery of gastrin heterogeneity in serum. Scand J Gastroenterol 1973;8:577-83.

(16.) Rehfeld JF. The new biology of gastrointestinal hormones. Physiol Rev 1998;78:1087-108.

(17.) Dockray GJ, Varro A, Dimaline R, Wang T. The gastrins: their production and biological activities. Annu Rev Physiol 2001;63:119-39.

(18.) Walsh JH, Isenberg JI, Ansfield J, Maxwell V. Clearance and acid-stimulating action of human big and little gastrins in duodenal ulcer subjects. J Clin Invest 1976;57:1125-31.

(19.) Rehfeld JF, Stadil F. Gel filtration studies on im munoreactive gastrin in serum from Zollinger-Ellison patients. Gut 1973;14:369-73.

(20.) Jensen S, Borch K, Hilsted L, Rehfeld JF. Progastrin processing during antral G-cell hypersecretion in humans. Gastroenterology 1989;96:1063-70.

(21.) Rehfeld JF, Stadil F, Rubin B. Production and evaluation of antibodies for the radioimmunoassay of gastrin. Scand J Clin Lab Invest 1972;30: 221-32.

(22.) de Magistris L, Rehfeld JF. A simple enzymatic procedure for radioimmunochemical quantitation of the large molecular forms of gastrin and cholecystokinin. Anal Biochem 1980;102:126-33.

(23.) Rehfeld JF, de Magistris L, Andersen BN. Sulfation of gastrin: effect on immunoreactivity. Regul Pept 1981;2:333-42.

(24.) Rehfeld JF, Gingras MH, Bardram L, Hilsted L, Goetze JP, Poitras P. The Zollinger-Ellison syndrome and mismeasurement of gastrin. Gastroenterology 2011;140:1444-53.

(25.) Rehfeld JF. Processing of precursors of gastroenteropancreatic hormones: diagnostic significance. J Mol Med 1998;76:338-45.

(26.) Rehfeld JF, Zhu X, Norrbom C, Bundgaard JR, Johnsen AH, Nielsen JE, et al. Prohormone convertases 1/3 and 2 together orchestrate the sitespecific cleavages of progastrin to release gastrin-34 and gastrin-17. Biochem J 2008;415: 35-43.

(27.) Bardram L. Progastrin in serum from Zollinger-Ellison patients. An indicator of malignancy? Gastroenterology 1990;98:1420-6.

(28.) Andersen BN, Petersen B, Borch K, Rehfeld JF. Variations in the sulfation of circulating gastrins in gastrointestinal diseases. Scand J Gastroenterol 1983;18:565-9.

(29.) Ellison EH, Wilson SD. The Zollinger-Ellison syndrome: re-appraisal and evaluation of 260 registered cases. Ann Surg 1964;160:512-30.

(30.) Isenberg JI, Walsh JH, Grossman MI. Zollinger-Ellison syndrome. Gastroenterology 1973;65: 140-65.

(31.) Bardram L, Stadil F. Effects of omeprazole on acid secretion and acid-related symptoms in patients with Zollinger-Ellison syndrome. Scand J Gastroenterol Suppl 1989;166:95-100.

(32.) Murugesan SV, Varro A, Pritchard DM Strategies to determine whether hypergastrinaemia is due to Zollinger-Ellison syndrome rather than a more common benign cause. Aliment Pharmacol Ther 2009;29:1055-68.

(33.) Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine 2006;85:295-330.

(34.) Stadil F, Rehfeld JF. Determination of gastrin in serum. An evaluation of the reliability of a radioimmunoassay. Scand J Gastroenterol 1973;8: 101-12.

(35.) McGuigan JE. Immunochemical studies with synthetic human gastrin. Gastroenterology 1968;54: 1005-11.

(36.) Rehfeld JF. Accurate measurement of cholecystokinin in plasma. Clin Chem 1998;44:991-1001.

(37.) Rehfeld JF, Lindholm J, Andersen BN, Bardram L, Cantor P, Fenger M, Ludecke DK. Pituitary tumors containing cholecystokinin. N Engl J Med 1987; 316:1244-7.

(38.) Zimmer T, Stolzel U, Bader M, Fett U, Foss HD, Riecken EO, et al. Brief report: a duodenal gastrinoma in a patient with diarrhea and normal serum gastrin concentrations. N Engl J Med 1995; 333:634-6.

(39.) Bardram L, Rehfeld JF. Processing-independent radioimmunoanalysis: a general analytical principle applied to progastrin and its products. Anal Biochem 1988;175:537-43.

(40.) Rehfeld JF, Goetze JP. The posttranslational phase of gene expression: new possibilities in molecular diagnosis. Curr Mol Med 2003;3:2538.

Jens F. Rehfeld, [1] * Linda Bardram, [2] Linda Hilsted, [1] Pierre Poitras, [3] and Jens P. Goetze [1]

[1] Departments of Clinical Biochemistry and [2] Gastrointestinal Surgery, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; [3] Department of Gastroenterology, CHUM L'Hopital Saint-Luc, Universite de Montreal, Montreal, Quebec, Canada.

[4] Nonstandard abbreviations: ZES, Zollinger-Ellison syndrome; CCK, cholecystokinin.

* Address correspondence to this author at: Department of Clinical Biochemistry (3014), Rigshospitalet, DK-2100 Copenhagen, Denmark. Fax +45-3545-2880; e-mail jens.f.rehfeld@rh.regionh.dk.

Received December 12, 2011; accepted February 22, 2012.

Previously published online at DOI: 10.1373/clinchem.2011.179929
Table 1. Probability of valid diagnostic
measurement of gastrin concentrations in plasma
from patients with both ZES symptoms and plasma
concentrations <1247 pg/mL (<600 pmol/L) with
the indicated commercial gastrin immunoassay kits,
as compared with measurements made with a
validated reference RIA. (a)

         Gastrin kit             Probability, %

Biohit                                 68
Assay Designs (Correlate-EIA)          77
DiaSorin                               77
DRG Diagnostics                        94
Euro Diagnostica                      100
Siemens                                90
MP Biomedicals                         87
Peninsula Laboratories                 81
Phoenix Pharmaceuticals ELISA          84
Phoenix Pharmaceuticals RIA            45
Siemens RIA                            97
US Biological                          68

(a) The probability calculations are based
on individual measurements presented in Rehfeld et al.
(24), which also provides the manufacturers'
names.
COPYRIGHT 2012 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Mini-Review
Author:Rehfeld, Jens F.; Bardram, Linda; Hilsted, Linda; Poitras, Pierre; Goetze, Jens P.
Publication:Clinical Chemistry
Article Type:Report
Geographic Code:1CANA
Date:May 1, 2012
Words:3579
Previous Article:A 54-year-old diabetic man with low serum cholesterol.
Next Article:The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters